169 related articles for article (PubMed ID: 31778838)
1. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
Yang X; Wang Y; Sun X; Bai X; Cui Q; Zhu H; Qian J; Chen Y; Sun S; Ji N; Liu Y
World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838
[TBL] [Abstract][Full Text] [Related]
2. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
Mizowaki T; Sasayama T; Tanaka K; Mizukawa K; Takata K; Nakamizo S; Tanaka H; Nagashima H; Nishihara M; Hirose T; Itoh T; Kohmura E
J Neurooncol; 2015 Sep; 124(2):165-74. PubMed ID: 26080800
[TBL] [Abstract][Full Text] [Related]
3. Expression of signal transducer and activator of transcription 3 (STAT3) in primary central nervous system diffuse large B-cell lymphoma: a retrospective analysis of 17 cases.
Vajpayee N; Hussain J; Tolocica I; Hutchison RE; Gajra A
J Neurooncol; 2010 Nov; 100(2):249-53. PubMed ID: 20446017
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
5. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Schorb E; Fox CP; Kasenda B; Linton K; Martinez-Calle N; Calimeri T; Ninkovic S; Eyre TA; Cummin T; Smith J; Yallop D; De Marco B; Krampera M; Trefz S; Orsucci L; Fabbri A; Illerhaus G; Cwynarski K; Ferreri AJM
Br J Haematol; 2020 Jun; 189(5):879-887. PubMed ID: 31997308
[TBL] [Abstract][Full Text] [Related]
6. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
[TBL] [Abstract][Full Text] [Related]
7. The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma.
Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Cheong JW; Kim YR; Lee JY; Jang JE; Kim Y; Min YH; Kim JS
Ann Hematol; 2017 Jul; 96(7):1163-1173. PubMed ID: 28508176
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
9. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
11. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma.
Komohara Y; Horlad H; Ohnishi K; Ohta K; Makino K; Hondo H; Yamanaka R; Kajiwara K; Saito T; Kuratsu J; Takeya M
J Clin Exp Hematop; 2011; 51(2):93-9. PubMed ID: 22104307
[TBL] [Abstract][Full Text] [Related]
12. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
13. Novel biomarker, phosphorylated T-LAK cell-originated protein kinase (p-TOPK) can predict outcome in primary central nervous system lymphoma.
Koh M; Hayakawa Y; Akai T; Hayashi T; Tomita T; Nagai S; Kuroda S
Neuropathology; 2018 Jun; 38(3):228-236. PubMed ID: 29575092
[TBL] [Abstract][Full Text] [Related]
14. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies.
Sethi TK; Reddy NM
Leuk Lymphoma; 2019 Jan; 60(1):6-18. PubMed ID: 29741421
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcome and prognostic factors in PCNSL.
Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
[TBL] [Abstract][Full Text] [Related]
16. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Grommes C; Rubenstein JL; DeAngelis LM; Ferreri AJM; Batchelor TT
Neuro Oncol; 2019 Feb; 21(3):296-305. PubMed ID: 30418592
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
[No Abstract] [Full Text] [Related]
20. Primary Central Nervous System Lymphomas of the Brain: A Retrospective Analysis in a Single Institution.
Lin TK; Yeh TH; Hsu PW; Chuang CC; Tu PH; Chen PY; Jung SM; Wei KC; Huang YC
World Neurosurg; 2017 Jul; 103():550-556. PubMed ID: 28363832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
